FDA Releases Guidance on Software in Prescription Drugs

In a landmark decision, the U.S. Food and Drug Administration finalized its guidance, “Regulatory Considerations for Prescription Drug Use-Related Software (PDURS),” clarifying that software distributed by or on behalf of prescription drug sponsors falls under the agency’s drug labeling authority. The guidance, after a multi‑year delay, requires sponsors to treat software as part of the drug’s labeling, affecting design, claims, and post‑market monitoring. For law firms advising pharmaceutical and biotechnology clients, the ruling signals a shift in how software‑dependent therapies are regulated: product developers must now incorporate software considerations into INDs, NDA submissions, and labeling updates, and ensure risk‑management plans address software functionality. Compliance teams should review existing contracts with software vendors, update IP assignments, and audit labeling for potential software‑related liability. Firms should also advise clients on potential changes to post‑marketing study designs and reporting obligations. The guidance is likely to affect product development timelines and regulatory strategy, and counsel should be prepared for increased scrutiny or potential enforcement actions if labeling fails to meet the new criteria.